Shionogi Archives - DelveInsight

Shionogi

Default Blog Image
Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in ...

Merck’s Gefapixant could become the first drug approved for Chronic CoughATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Phar...


Gilead
Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal

Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndromeTetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in ...


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.